Asset Details
Do you wish to reserve the book?
Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B
Do you wish to request the book?
Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B
2025
Overview
Chronic hepatitis B virus (HBV) infection is a major health problem that leads to approximately one million deaths every year worldwide. Mother-to-child transmission (MTCT) is the major cause of chronic HBV infection. HBV e antigen (HBeAg) is a secretory viral protein and modulates the immunological landscape of the newborn to promote HBV persistence. HBeAg actively reprograms innate and adaptive immunity. Mechanistically, HBeAg regulates macrophage polarization, suppresses dendritic cell and natural killer (NK) cell activities, impairs T cell and B cell functions, and promotes the expansion of myeloid-derived suppressor cells (MDSCs). These multifaceted effects contribute to immune tolerance and persistent HBV infection in the offspring of carrier mothers. Clinically, HBeAg status is a critical determinant for MTCT risk stratification and intervention, particularly in resource-limited settings. Despite advances in neonatal immunoprophylaxis and maternal antiviral therapy, residual transmission of HBV persists. Emerging approaches targeting HBeAg directly or restoring antiviral immunity offer promising avenues for breaking immune tolerance and achieving HBV elimination. This review summarizes current understanding of HBeAg-mediated immune modulation and highlights strategies that are being used to disrupt MTCT and treat HBV patients.
Publisher
MDPI AG
Subject
/ Antigens
/ Antiviral Agents - therapeutic use
/ Embryos
/ Female
/ Fetuses
/ Genes
/ Hepatitis B e Antigens - immunology
/ Hepatitis B virus - immunology
/ Hepatitis B, Chronic - drug therapy
/ Hepatitis B, Chronic - immunology
/ Hepatitis B, Chronic - transmission
/ Hepatitis B, Chronic - virology
/ Humans
/ Infectious Disease Transmission, Vertical - prevention & control
/ Kinases
/ mother-to-child transmission
/ Mothers
/ Neonates
/ Placenta
/ Pregnancy Complications, Infectious - immunology
/ Pregnancy Complications, Infectious - virology
/ Proteins
/ T cells
/ Vaccines
